The aim of synthetic biology is to make genetic systems more amenable to engineering, which has naturally led to the development of computer-aided design (CAD) tools. Experimentalists still primarily rely on projectspecific ad hoc workflows instead of domain-specific tools, which suggests that CAD tools are lagging behind the front line of the field. Here, we discuss the scientific hurdles that have limited the productivity gains anticipated from existing tools. We argue that the real value of efforts to develop CAD tools is the formalization of genetic design rules that determine the complex relationships between genotype and phenotype.
The aim of synthetic biology is to make genetic systems more amenable to engineering, which has naturally led to the development of computer-aided design (CAD) tools. Experimentalists still primarily rely on projectspecific ad hoc workflows instead of domain-specific tools, which suggests that CAD tools are lagging behind the front line of the field. Here, we discuss the scientific hurdles that have limited the productivity gains anticipated from existing tools. We argue that the real value of efforts to develop CAD tools is the formalization of genetic design rules that determine the complex relationships between genotype and phenotype.
Computer-aided design tools for synthetic biology Several groups have been developing computer-aided design (CAD) solutions for synthetic biology [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , yet the transcriptional complexity of published artificial gene networks has been leveling off since 2005 [11] . After 10 years of high expectations and hype in synthetic biology, engineering of biological systems has proved more challenging than anticipated [12] . The lack of sufficient tools in synthetic biology has spurred intense efforts to develop CAD software. Unfortunately, experimental synthetic biologists still rely largely on project-specific ad hoc development processes that combine construct assembly, data collection, data analysis and mathematical modeling.
Five recent reviews have comprehensively covered the current state of computational tools for synthetic biology [13] [14] [15] [16] [17] . Thus, we limit our description of these efforts to a brief general overview. We also constrain the review to software specific to synthetic biology by excluding the many commercial software packages that are useful to synthetic biologists, but intended for a broader user base. CAD tools for synthetic biology facilitate the design of larger systems from smaller genetic parts by providing users with visual, textual or programming-language-like interfaces, or automatically generating designs from intended function. These tools assume that data such as sequence and description details are attached to each part by the user or are in some database. The aggregated parts sequences can then be leveraged to produce the corresponding physical DNA. Many tools include some level of functional modeling capabilities, which rely on user provision of the necessary equations and/or parameters ( Figure 1 ). As a result, most projects require the use of multiple software tools that need to be integrated in software stacks. Box 1 discusses some of the technical and legal challenges that could hamper the integration of software tools.
Thus far in synthetic biology, relatively simple design goals such as 'exhibits oscillations' [18] have advanced to increasingly sophisticated goals such as 'fast, robust, tunable oscillators' [19] or 'synchronized oscillators' [20] . As the field moves towards real-world applications [21] , tools that can adequately predict functionality from design will be indispensible. Moreover, designers need to begin considering alternative design approaches and corresponding comparison metrics [22] to move beyond proof-of-concept designs. Recently announced design-to-specification competitions such as CAGEN (Competitive Assessment of Genetically Engineered Networks) and GenoCon (International Rational Genome Design Contest) are aimed at addressing this need ( Table 1) .
The goal of this paper is first to explore the scientific hurdles that have limited the productivity gains anticipated for existing CAD tools, and second to argue that the real value of these efforts is not in promised productivity gains, but in the formalization of genetic design rules. Formalizations inherently test commonly held conceptions of how genetic systems work and consequently drive investigation into one of the most fundamental questions of genetics: how does phenotype arise from complicated networks of elements coded in the genotype [23] ?
Slow maturation of electronic design automation CAD tools are ubiquitous in nearly all fields of engineering. They provide two primary functions: simplification of common tasks and creation of design representations convenient for communication and evaluation. For example, blueprints are designed much faster on a computer than by traditional drafting. Moreover, CAD tools can generate layouts of each floor, 3D renderings of a building, or models of the thermal performance of a building.
In electronics, the development of consistent suites of CAD tools is called electronic design automation (EDA). EDA utilizes iterative design flows, in which key design processes are looped back on themselves until the design meets the specifications required. Abstract representations of an electronic design in EDA can be organized into a hierarchy consisting of a high-level description, logical description and physical layout.
The spectacular success of EDA over the last 50 years [24] provides an inspiring model for synthetic biology. The synthetic biology counterpart of EDA is sometimes referred to as bio-design automation (Table 1) . However, the alternative name genetic design automation (GDA) may better emphasize the fact that synthetic biology focuses more on engineering of DNA molecules than other biological objects [25] . Many have proposed that synthetic biologists can leverage expertise in the design of electrical circuits, and in the same way GDA can draw from the development of EDA. In EDA, hardware description languages (HDLs) are a special category of programming languages used to formally describe immensely complicated designs in a compact way. These languages rely extensively on the existing abstraction that digital circuits operate under the laws of Boolean algebra, which facilitates reliable design of hugely complex circuits.
This assumption does not exist for GDA. Exploratory work on a HDL for GDA has progressed under the assumption that similar enabling assumptions will emerge [10] . In parallel, efforts within the EDA community to describe analog and mixed analog-digital circuits with HDLs are ongoing. The challenges of extending HDLs to analog circuits are very similar to the challenges faced in GDA, and indeed some works have explored these similarities [26, 27] .
The next sections describe three difficult problems that need to be solved before the level of automation in EDA can be achieved with GDA. There is mounting evidence that the first generation of GDA tools will not be able to ignore some of the most challenging problems currently faced by the EDA community. Figure 1 . GDA design flow. Synthetic biology projects typically rely on iterative workflows composed of different tasks. Emerging GDA tool chains rely on numerous software applications that support different phases of the project workflow. The development of a genetic switch [72] will first involve expression of the design objective as a list of quantitative requirements: input toggle thresholds, noise margins, switching response time, etc. Once the objective is specified, it is possible to develop a list of genetic parts useable for the project. The choice of biological parts will involve factors such as use of the parts in prior projects, quality of the data characterizing the parts function, or intellectual property considerations. Formalization of design rules often takes place in parallel with parts library development. Design rules may cover issues such as whether it is acceptable to have polycistronic expression cassettes or if the design should be split between different plasmids. Only after parts have been selected and a strategy has been agreed on is it possible to start designing constructs. In the fabrication phase, the construct is assembled, usually by combining de novo gene synthesis and cloning of existing DNA sequences. Operators use molecular biology software suites to facilitate assembly or to order the sequence from a gene synthesis company. Experimentalists insert the synthetic DNA molecule into the host of choice and collect phenotypic data. Experimental data are then processed, for example by reducing microscopy images to time series of quantitative data. Performance is evaluated by considering simulations, experimental data and the original specifications. At nearly every stage, software interacts with databases to reuse past work or to store current work for future use. The shaded area delimited by dashes denotes stages facilitated by synthetic biology CAD software, whereas other stages are handled by more general purpose software. of CAD tools, but rather by three difficult scientific challenges: (i) predictability of components, (ii) decoupling of design and fabrication and (iii) experimental characterization methods. These outstanding questions are summarized in Box 2 and discussed in more detail below.
TRENDS in Biotechnology
Off-the-shelf components One of the popular visions for synthetic biology describes catalogs of clearly defined genetic parts that can be easily combined into larger genetic constructs with predictable biological function. This vision motivated the development of the BioBrick assembly standard and the Registry of Standard Genetic Parts, a database of BioBrick compatible parts ( Table 1 ). Tools that aggregate models of basic genetic components to form system-scale models are being developed [1, 2, 4, 28] , but the lack of data sheets listing quantitative parameters for parts behavior has hampered the use of these tools for the design of artificial gene networks [29] . Projects such as BIOFAB (Table 1) are attempting to address this issue by characterizing large numbers of parts and standardizing data collection techniques [30] . Recent efforts to quantitatively characterize the effects of different parts on gene expression are revealing a complex landscape of context dependence that somewhat challenges the assumption that parts can be characterized in isolation. For instance, it was first assumed by many in the field that the RBS sequence determines translation efficiency in prokaryotes independently from the downstream coding sequence. However, sequences around the translation start site can influence the secondary structure of the mRNA, which plays a crucial role in the translation rate [31] . Tools that utilize thermodynamic models [32, 33] are now available to predict the translation initiation efficiency in prokaryotes using sequences both upstream and downstream of the translational start site. Coupling between translation and transcription elongation rates [34] Box 1. Software integration A crucial evolution in EDA has been the integration of previously independent design flow steps as the assumptions allowing for isolation have eroded. Device physics are infringing on the Boolean assumption, layout and function are intermingling, and testing is becoming more interlinked with design. Beginning with the development of centralized CAD frameworks in the early 1980s, this progression has led to integrated CAD tools in EDA [41, 66] that have evolved onto modular tools that can communicate with one another. In GDA, design flow stages are intrinsically interlaced, and thus tools should be designed for integration rather than forcing them apart. In this perspective, the importance of ongoing efforts to develop open source software frameworks and data exchange standards such as the Synthetic Biology Open Language (SBOL) ( Table 1 ) cannot be underestimated [67, 68] .
As the field matures, many GDA applications will need to be integrated into custom software stacks, as is happening in mainstream bioinformatics [69] . Different integration models have different legal implications. One model consists of integrating data by accessing specialized web services. This model is illustrated by the rapid development of scientific workflow systems that facilitate this data integration [70, 71] . The model is attractive because the tools only need to share a common language such as SBOL, which saves the end user the effort of installing, maintaining and integrating different software components. However, there are many potential difficulties with this integration model: (i) dependence on computational services provided on a volunteer basis by a third party creates potential vulnerability; (ii) movement of large amounts of data to web-hosted services can be inefficient; and (iii) sending sensitive data to a third-party server may be undesirable. The other approach to software integration consists of integration of different applications executed by the computational resources of the end user. This integration model raises some software licensing issues. To prevent corporations from segmenting GDA markets into proprietary silos as in EDA, it would be prudent to foster the emergence of a vibrant GDA software development community. In addition to avoidance of market lockout resulting from proprietary software, it is crucial to ensure that the code base developed by the GDA community is free from hidden intellectual property claims and is licensed under permissive terms that allow academic and corporate stakeholders to reuse existing code bases. also represents a challenge to the standardization of components, although the assumption that initiation, and not elongation, is the rate-limiting step in transcription may be a valid approximation. As a result, tools that can predict behavior based on sequence, thermodynamics or other methods are emerging as increasingly attractive. The above issues can be avoided by characterizing on a gene-by-gene or device-by-device basis, a trend that is already apparent in the field [11] . Creation of device variants or automatically generated devices [35] should consider the many context dependences that affect parts. However, even such low levels of granularity might prove to have unexpected context dependences. Computational studies, inspired by impedance matching in electronics, have demonstrated an effect termed retroactivity, in which the performance of one genetic device is influenced by connecting a downstream device [36, 37] . Just as electronic circuit designers are currently encountering major power limitations, synthetic biologists are almost certain to experience limits imposed by the many ingredients necessary for gene expression. How the availability of resources within a cell impacts the performance of individual genetic components and devices will also become an important consideration.
Decoupling of design and fabrication
Historically, recombinant DNA technologies were so limited that fabrication constrained design to a point at which software focused almost entirely on assisting in cloning rather than in design of function. The recent availability of generic DNA fabrication methods, including standardized assembly of genetic parts or de novo gene synthesis [38] , has led to the emergence of DNA sequence design as a new scientific problem [39, 40] . Because it is now possible to assume that generic DNA fabrication processes can assemble any sequence that genetic engineers imagine, design and fabrication tend to be considered orthogonal engineering problems.
In EDA, assumption of Boolean abstraction has facilitated consideration of fabrication as mostly orthogonal to the rest of the design process. As circuit densities have rapidly increased, fabrication constraints have become more closely intertwined with other constraints, such as timing delays and power consumption [41] . Consequently, increasingly integrated tools consider constraints imposed by multiple design domains simultaneously. Genetic design is still moving away from fabrication technologies that constrain the design space to achieve complete independence between design and manufacture. For instance, BioBrick assembly standards have moved from the original standard precluding assembly of fusion proteins (BBF RFC 10) to proposed standards that allow fusions [42] or scarless assembly (BBR RFC 26, 39) . Most recently, single-step assembly methods have become popular [43] .
Despite the simplification that decoupling offers, there are distinct advantages to recoupling of design and manufacturing during the design phase. Poor design strategies can create manufacturing problems. For example, repeated use of the same parts can cause sequence verification difficulties and structural instabilities [44] . Sequences with high GC content are notoriously difficult to amplify. Even though experienced gene synthesis companies will be able to synthesize most DNA sequences ordered by their customers, price and time to delivery vary greatly with sequence complexity. Ignoring such manufacturing constraints during the design phase will significantly increase the cost and duration of GDA cycles. Many projects require the characterization of large numbers of design variants, so the cost and time for fabrication of these designs is still one of the bottlenecks of the GDA loop. Sophisticated design strategies are necessary to formalize manufacturing constraints [45] and optimize fabrication without serious detriment to function. For example, tools that can adjust codon bias or match non-unique sequences to function [32, 33, 35] could ease manufacturing concerns. Sample tracking tools could suggest reuse of sequence segments to result in shorter and cheaper assembly cycles. Algorithms to optimize fabrication processes [46] will have to be connected to design tools to give designers an immediate appreciation of the manufacturing cost of candidate designs.
Parts characterization
The problem of part definitions extends to the ways in which experimental data are collected, used and shared. Models vary from project to project and typically have only one or two fluorescent reporters as measured outputs. Models typically have many more parameters to estimate, so identification of parameter sets that are predictive from the many possible sets that match a given data set is difficult. The combination of the range of measurement techniques used in the laboratory and the unknown impact of even small changes in experimental conditions means that standardization and reuse of collected data are challenging.
Although not necessarily an explicit step in standard EDA design flows, design for test (DFT) is a background constraint throughout the process. As electronic circuits have become more complex, validation testing has become correspondingly more difficult. First, immense complexity makes exhaustive validation intractable, so intelligent minimization of test programs has evolved, along with sophisticated testing equipment [47] . Second, the density of modern chips has meant that accessing nodes on internal layers without unintended performance effects is a major problem. In living cells, the problem is much worse. Unknown cellular mechanisms, genetic instabilities, molecular noise, measurement accuracy and inability to measure key components have prevented the verification of synthetic biology designs.
DFT in GDA starts by ensuring consistency between the design specification, experimental characterization methods and mathematical paradigms used to model the behavior. For example, models based on deterministic equations can be supported by cell culture assays, whereas stochastic models call for single-cell observations. Experimental design, common in some other engineering fields and recently emerging as a hot topic in systems biology [48] , can guide experimentalists to optimal sets of measurements and avoid non-informative data collection. Depending on the system, this approach can also predict data sets that will determine all model parameters to [49] . Similar techniques are frequently used in EDA to design intelligent testing programs, particularly for system-on-a-chip designs in which analog components commingle with digital circuits. If experimental characterization is not considered during the design phase, this may lead to designs that simply cannot be adequately tested.
Review
The problem of collecting time-course data inside living cells has been transformed by the emergence of fluorescent proteins. However, just as making an internal node in a chip accessible for testing affects its performance, the maturation rate and protein half-life buffer fluorescence signals from physiological events of interest [50] . Unfortunately, even parameters related to measurements such as the in vivo maturation rate of fluorescent proteins are difficult to determine accurately due to cell-to-cell variation and unknown dependencies on host strain, metabolic state, and environmental conditions. In addition, the use of genes tagged with fluorescent domains is common, but the effects are poorly understood. For example, how does a fluorescent tag affect the degradation rate of the fusion protein? Experimental work is needed to answer such questions.
New measurement devices will greatly facilitate the ability to determine in vivo parameter values and their dependence on the continuously variable cellular environment. The emergence of time-lapse fluorescent microscopy has enabled scientists to measure the dynamics of molecular mechanisms in individual cells [51] . This technique currently requires custom integration of optical equipment, image processing software and microfluidic systems [52, 53] . Noise analysis connects processed data to models of the underlying mechanisms [51] . Current image processing and analysis are typically post-processing steps, but these prototypes prefigure a new generation of instruments that will acquire raw images, process them in real time, and implement data reduction algorithms to extract high-level statistics for comparison with design-phase models (Figure 2) . Microfluidic systems will facilitate complicated input control of environmental parameters that should open avenues for the application of some advanced testing techniques used in EDA DFT, such as frequency response analysis.
A scientific renewal Several authors recently argued that synthetic biology will lead to a better understanding of biology [54, 55] . In this spirit, we would like to question the assumption that the immediate value of GDA lies in its potential to accelerate the progress of experimental synthetic biologists. In the 
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Data reduction
Image and signal processing Figure 2 . New instruments that connect design and experiment. (a) Use of time-lapse microscopy to characterize the dynamics of gene networks requires the development of a custom suite of image and signal processing software, along with data reduction algorithms. The mathematical models used to reduce movies to high-level statistics are necessarily related to the models used to design the gene network because experimental data ultimately need to be reconciled with model predictions. (b) Microscopy movies have traditionally been analyzed in a post-processing step. However, it is conceivable that in the near future, data analysis will be performed in real time by the computer that controls the microscope and the microfluidic system, which should provide the user with an experience similar to the use of a flow cytometer. The operator could also use this information to manually interact with the cells under observation. Alternatively, a control algorithm could be developed to program the instrument to take specific actions such as changing the growth medium in response to specific behaviors by the cell populations. short term, efforts to develop GDA tools may be better justified as attempts to formalize genetic design principles. The assumption that models used in engineering can be extrapolated to biology can easily and rightfully be challenged by biologists. A more effective way of using GDA to initiate dialog between engineers and life scientists might be to present GDA models as formal and compact representations of biological hypotheses. GDA would then become a framework to express and test biological hypotheses, a form of scientific investigation common in the life sciences [56] [57] [58] .
It is important to consider here two fundamental differences between EDA and GDA. The dynamics of genetic networks is largely determined by the interactions between large macromolecules confined to the small volume of a living cell. As a result, the dynamics of a genetic network is inherently stochastic in nature. There is even mounting evidence that many regulatory processes are based on molecular noise instead of merely attempting to mitigate its negative effects [59] . Electronic circuits use so many electrons that they behave deterministically. However, a consequence of the miniaturization and increasing power efficiency of silicon devices is a drastic reduction in electron fluxes and a concomitant increase in intrinsic electronic noise. It will be interesting to see if and how the EDA and GDA communities will work together to solve the problems associated with design automation of noisy systems.
Another important difference between GDA and EDA is that complexity in EDA was derived, whereas complexity in GDA evolved. EDA has progressed via structured and rational improvements in the mathematical formalisms that express physical realities to incrementally allow increasingly higher complexity. As a result, the emergence of high-level function can always be traced to the lowest-level components. However, because genetic systems evolved via random mutation, it is not clear if they follow rigorous design rules, and we cannot yet trace high-level function back to low-level components in most cases. Synthetic biologists are walking in the footsteps of 50 years of effort by molecular geneticists to understand the design rules of genetic systems. However, the engineering mindset provides a new spark. Understanding of a genetic mechanism is truly put to the test when an engineer attempts to use the general principle to build something new. Formalization of these principles tests the theory and opens new areas of investigation when the theory is found lacking. A prime example of this is the aforementioned RBS calculator. Attempts to use 'standard' ribosome binding sites failed and led to predictive thermodynamic models. The possibility of deoptimizing the sequence of viral genes by taking advantage of codon pair bias [60, 61] is opening new research directions to gain a better understanding of translation [62] . At a higher level of organization, refactoring of the T7 genome resulted in reduced fitness that it is not completely understood [63] .
In its current state, synthetic biology remains painfully slow, prohibitively expensive and excessively labor-intensive. As an example, consider the progression from two 2002 theoretical papers on genetic oscillators [64, 65] to corresponding experimental publications in 2008 [19] and 2010 [20] . The unifying vision of a seamless GDA flow provides a collaborative framework for large interdisciplinary teams rather than relying on exceptional individual investigators familiar with all aspects of the design process. There is still a great deal of foundational work and biological discovery remaining before GDA materializes into suites of software tools facilitating design to specification entirely in silico. In the short term, closing of some of the capability gaps will catalyze the emergence of more integrated teams to better handle the complex interdependence among design, fabrication and measurement. The tools these teams will generate may not have the elegance of an integrated solution, but they will provide new computational resources that should percolate beyond the confines of the synthetic biology community to benefit a larger population of life scientists.
